Biosimilar Medicines 12th EGA International Conference coordinated by the European Biosimilars Group, a Sector Group of the EGA
April 3 - 4, 2014 - London BEEuropean Generic medicines Association (EGA)
trudy@gpaconferences.com
Phone:+31-6-41190824
The EU Biosimilars Flagship Event 12th EGA International Biosimilar Medicines Conference coordinated by the European Biosimilars Group, a Sector Group of the EGA 3-4 April 2014 - The Tower Hotel (St. Katherine’s Way, London E1W 1LD, UK) Come and meet the leading EU and International Regulators and Experienced EU Companies • Current status and future outlook of the biosimilar medicines market • Biosimilars business opportunities beyond the EU and the USA • Next steps of the “Tajani initiative” and the European Commission industrial policy strategy • Update on biosimilars utilisation and best practices around Europe supporting uptake • Outcome of a study report on the sustainability of the biosimilar medicines industry • Most recent developments regarding EMA pioneering guidelines • Progress on global framework for biosimilar development: insight from EMA, FDA and KFDA • EU extensive experience with biologics prescribing, naming, traceability and pharmacovigilance • Extrapolation of indications: regulators’ experience with assessment of the first biosimilar monoclonal antibody • Biosimilarity concept: a paradigm shift for many key stakeholders • Biosimilars for doctors: interactive panel session with renowned clinicians in rheumatology and oncology Join us for the interactive Pre-conference Biosimilars Master Class Global Development of Biosimilars – vision or reality? Where is the US? With Gillian Woollett, MA, DPhil and Mateja Urlep, respectively Senior Vice President, Avalere Health and Founder & CEO, TikhePharma, where you can address all your questions in a shared and informal setting” (Open to conference delegates who have registered separately for the Master Class)